Core Viewpoint - The significant upward revision of profit forecasts for Shenghua Co. (600201.SH) by Kaiyuan Securities reflects a strong confidence in the company's growth prospects, particularly driven by the development of the African swine fever vaccine [1][6]. Group 1: Profit Forecast Adjustments - In late October 2025, Kaiyuan Securities provided a cautious profit forecast for Shenghua Co. for 2025-2027, estimating net profits of 1.88 billion, 3.52 billion, and 5.08 billion respectively [2]. - By January 8, 2026, the profit forecast for 2026 was dramatically increased to 7.12 billion, nearly doubling the previous estimate, while the 2027 forecast rose by over 138% to 12.11 billion [2]. Group 2: Key Drivers of Growth - The major adjustment in profit forecasts is primarily attributed to the unexpected progress in the research and development of the African swine fever subunit vaccine, with Shenghua Co. being the first and only company in China approved for clinical trials [3]. - The vaccine is expected to create an incremental market size of approximately 84 billion in China, positioning Shenghua Co. as a significant beneficiary due to its first-mover advantage [3]. Group 3: Traditional Business Performance - Besides the potential of the African swine fever vaccine, Shenghua Co.'s traditional business is also showing steady growth, with a 50% year-on-year increase in sales of foot-and-mouth disease vaccines in the first three quarters of 2025 [4]. - Other vaccine products, including those for ruminants, poultry, and pets, are also experiencing strong growth, supported by a robust investment in R&D, which accounted for 13.51% of revenue in the first half of 2025 [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price based on the last closing price of 10.62 [1] Core Insights - The company's revenue for the first three quarters of 2025 reached 1.042 billion yuan, representing a year-on-year increase of 7.38%, while the net profit attributable to shareholders was 161 million yuan, a decrease of 4.85% year-on-year. In Q3 2025 alone, revenue was 423 million yuan, up 17.76% year-on-year, and net profit was 101 million yuan, an increase of 116.40% year-on-year [4][5] - The core products continue to see significant growth, particularly in the swine vaccine segment, with sales of foot-and-mouth disease vaccines increasing by 50% year-on-year, and diarrhea vaccines seeing a 120% increase in revenue. The company is also making steady progress in developing new vaccines, including a novel mRNA vaccine for feline infectious peritonitis [5][7] Financial Performance Summary - The company forecasts revenues of 1.569 billion yuan for 2025, 1.851 billion yuan for 2026, and 2.073 billion yuan for 2027, with net profits projected at 283 million yuan, 320 million yuan, and 335 million yuan respectively. The corresponding EPS for these years is expected to be 0.25 yuan, 0.29 yuan, and 0.30 yuan, with PE ratios of 42.57, 37.67, and 35.91 respectively [5][7][9] - The gross margin is projected to be 54.00% in 2025, with a net profit margin of 18.03% [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a recovery in performance, with a focus on the orderly advancement of non-epidemic vaccine clinical trials. The revenue for Q1-Q3 2025 reached 1.042 billion yuan, a year-on-year increase of 7.38%, while the net profit attributable to shareholders was 161 million yuan, a year-on-year decrease of 4.85%. In Q3 alone, revenue was 423 million yuan, up 17.76% year-on-year, and net profit increased significantly by 116.40% year-on-year [2][3] - The company maintains its profit forecast for 2025-2027, expecting net profits of 188 million yuan, 352 million yuan, and 508 million yuan respectively, with corresponding EPS of 0.17 yuan, 0.32 yuan, and 0.46 yuan. The current stock price corresponds to PE ratios of 65.4, 35.0, and 24.3 times for the respective years [2] Summary by Sections Financial Performance - For Q1-Q3 2025, the company reported a revenue of 1.042 billion yuan, a 7.38% increase year-on-year, and a net profit of 161 million yuan, down 4.85% year-on-year. Q3 revenue was 423 million yuan, up 17.76% year-on-year, with net profit soaring by 116.40% year-on-year [2] - The company forecasts net profits of 188 million yuan in 2025, 352 million yuan in 2026, and 508 million yuan in 2027, with EPS projected at 0.17 yuan, 0.32 yuan, and 0.46 yuan respectively [2][3] Market Position and Growth - The company is expanding its market share in the competitive pig vaccine sector, with Q1-Q3 2025 sales of pig foot-and-mouth disease vaccines increasing by 50% year-on-year. The revenue from non-foot-and-mouth vaccines also saw significant growth, with diarrhea vaccine revenue up 120% year-on-year [3] - Direct sales channels for poultry vaccines showed strong performance, with a 40% year-on-year increase in direct sales revenue. The company is also expanding its international business, with revenue growth exceeding 16 million yuan in Q1-Q3 2025 [3] Research and Development - The company emphasizes stable operations and innovation in R&D, with R&D expenses of 96 million yuan in Q1-Q3 2025, a 9.08% increase year-on-year. The non-epidemic vaccine development is progressing, with the first clinical trial expected to begin by the end of December 2025 [4]